Shanghai Huikai Medical Technology Co., Ltd, a China-based urology device manufacturer, has reportedly raised tens of millions of renminbi in a Series A+ financing round, led exclusively by Beijing NatonTechnology Group Co., Ltd. The funds raised will be directed towards clinical studies and market promotion efforts.
HuiKai Medtech’s Core Product and Clinical Progress
Founded in 2018, Huikai Medical Technology has developed its flagship product, UroStent, a prostate stent system that does not require general anesthesia or a cystoscope for localization and release. This innovative device has entered clinical trials at Sun Yat-sen Memorial Hospital, marking a significant step in the company’s development and commercialization journey.
Market Potential and Clinical Significance
The investment by Beijing NatonTechnology Group underscores the potential of Huikai Medical Technology’s UroStent system in addressing the needs of the urology market. The product’s ability to simplify the procedure for prostate stent placement without general anesthesia has the potential to improve patient outcomes and reduce healthcare costs.-Fineline Info & Tech
